Physician profile
Evan Gray
NPI 1134625593
$55,039.93
in general payments reported to CMS, 2019-2025
51 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $1,234 · 2023: $2,137 · 2024: $21K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $14K · Consulting Fee: $14K · Travel and Lodging: $4,715 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,263.00 |
| Food and Beverage | $13,874.51 |
| Consulting Fee | $13,600.00 |
| Travel and Lodging | $4,715.06 |
| Education | $230.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $41,432.58 | 2021-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $2,309.79 | 2023-2025 | |
| Medtronic, INC. | $1,529.69 | 2022-2025 | Percept PC Brainsense, Inceptiv |
| Boston Scientific Corporation | $1,192.38 | 2022-2025 | Vercise |
| Lilly USA, LLC | $772.31 | 2023-2025 | Emgality, Kisunla, Amyvid |
| Pfizer INC. | $664.50 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $608.59 | 2023-2025 | Austedo Xr, Austedo Xr |
| Amneal Pharmaceuticals LLC | $599.21 | 2023-2025 | Rytary, Crexont |
| Mdd US Operations, LLC | $478.37 | 2024-2025 | Gocovri |
| Biogen, INC. | $467.13 | 2024-2025 | Tysabri, Leqembi, Spinraza |
| Emd Serono, INC. | $388.71 | 2023-2025 | Mavenclad |
| Ucb, INC. | $385.68 | 2023-2025 | Rystiggo, Nayzilam, Briviact |
| Lundbeck LLC | $375.18 | 2023-2025 | Vyepti, Rexulti |
| Axsome Therapeutics, INC. | $332.48 | 2025 | Symbravo, Sunosi |
| Neurelis, INC. | $321.91 | 2023-2025 | Valtoco |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $314.29 | 2023-2025 | Wakix |
| Insightec,INC | $265.78 | 2022-2025 | Exablate |
| Merz Pharmaceuticals, LLC | $208.51 | 2024 | Xeomin |
| Eisai INC. | $204.30 | 2023-2025 | |
| Kerecis Limited | $203.02 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Argenx US, INC. | $199.70 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Kyowa Kirin, INC. | $164.88 | 2023-2024 | Nourianz |
| Novartis Pharmaceuticals Corporation | $159.78 | 2023-2025 | |
| Averitas Pharma INC. | $138.96 | 2023-2025 | Qutenza |
| Tanabe Pharma America, INC. | $124.21 | 2024-2025 | Radicava |
| Amgen INC. | $118.98 | 2025 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $106.74 | 2023-2025 | Nuedexta, Rexulti |
| Revance Therapeutics, INC. | $101.86 | 2024-2025 | Daxxify |
| Csl Behring | $99.52 | 2023-2024 | Hizentra |
| Acadia Pharmaceuticals INC | $83.09 | 2023-2024 | Nuplazid |
| Idorsia Pharmaceuticals US INC | $79.72 | 2023-2025 | Quviviq, Quviviq |
| Ge Healthcare | $67.10 | 2024 | |
| Supernus Pharmaceuticals, INC. | $53.13 | 2025 | Qelbree |
| Celgene Corporation | $52.36 | 2024-2025 | Zeposia |
| Avadel Cns Pharmaceuticals, LLC | $46.89 | 2024 | Lumryz |
| Impel Pharmaceuticals LLC | $45.73 | 2024 | Trudhesa |
| Jazz Pharmaceuticals INC. | $40.46 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $35.19 | 2024 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $32.76 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.20 | 2024 | Hyqvia |
| Vanda Pharmaceuticals INC. | $24.92 | 2025 | Ponvory |
| 3b Medical, INC. | $24.63 | 2025 | Luna |
| Noctrix Health, INC. | $24.60 | 2025 | Nidra |
| Abbott Laboratories | $23.97 | 2024 | Infinity |
| Impel Pharmaceuticals INC. | $23.10 | 2023 | Trudhesa |
| Viz.Ai, INC. | $20.64 | 2022 | |
| Azurity Pharmaceuticals, INC. | $19.85 | 2025 | Horizant |
| Astrazeneca Pharmaceuticals LP | $16.46 | 2025 | Wainua |
| Acorda Therapeutics, INC | $13.89 | 2023 | Ampyra, Inbrija |
| Electronic Waveform Lab, INC. | $12.54 | 2025 | |
| Travere Therapeutics, INC. | $1.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.